Snapshot from Jul 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / ResMed sells MatrixCare to Frazier
Business divestiture

ResMed sells MatrixCare to Frazier

Analysis based on 9 articles · First reported Jul 07, 2026 · Last updated Jul 07, 2026

Sentiment
10
Attention
3
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The sale allows ResMed to sharpen focus on its core sleep and connected care markets, potentially improving growth prospects and operational efficiency. Frazier Healthcare Partners gains a leading post-acute care technology platform, with plans to invest in product innovation.

healthcare technology medical devices software
Event Summary

ResMed (NYSE: RMD, ASX: RMD) announced on July 7, 2026, that it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused on healthcare. MatrixCare provides software solutions to over 15,000 providers in skilled nursing, senior living, long-term care, and home health and hospice. The divestiture aligns with ResMed's 2030 strategy to focus on high-growth sleep health, breathing health, and connected home-based care. The transaction is expected to close in the first quarter of ResMed's fiscal year 2027, subject to regulatory approvals. ResMed will retain its other software businesses, Brightree and MEDIFOX DAN. The financial impact will be disclosed in future filings.

Key Actions
90 ResMed agreed to sell Frazier Healthcare Partners
Entities Involved
stock
ResMed
ResMed is the seller, divesting MatrixCare to streamline its portfolio and focus on high-growth sleep and connected care markets, which may enhance long-term value.
Importance 100.0 Sentiment 15.0
priv
Frazier Healthcare Partners
Frazier Healthcare Partners is the buyer, acquiring MatrixCare to expand its post-acute care technology platform and invest in innovation.
Importance 80.0 Sentiment 10.0
priv
MatrixCare
MatrixCare is the divested business, a software provider for post-acute care, which will continue operations under new ownership with a dedicated focus.
Importance 70.0 Sentiment 5.0
per
Mick Farrell
Mick Farrell, Chairman and CEO of ResMed, announced the deal and emphasized portfolio management and long-term growth.
Importance 30.0 Sentiment 5.0
per
Ryan Lucero
Ryan Lucero, General Partner at Frazier Healthcare Partners, expressed enthusiasm for partnering with MatrixCare and investing in product innovation.
Importance 20.0 Sentiment 5.0
govactor
United States — United States Securities and Exchange Commission
The SEC received a Form 8-K from ResMed regarding the transaction, fulfilling regulatory disclosure requirements.
Importance 10.0 Sentiment 0.0
exch
New York Stock Exchange
ResMed is listed on the NYSE (ticker RMD), and the transaction may affect its stock performance.
Importance 5.0 Sentiment 0.0
exch
Australian Securities Exchange
ResMed is also listed on the ASX (ticker RMD), and the divestiture may influence its share price on that exchange.
Importance 5.0 Sentiment 0.0
Relationships
United States — United States Securities and Exchange Commission related ↔ New York Stock Exchange
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.